Reporting of Resistance Training Dose, Adherence, and Tolerance in Exercise Oncology
Open Access
- 20 August 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine & Science in Sports & Exercise
- Vol. 52 (2), 315-322
- https://doi.org/10.1249/mss.0000000000002127
Abstract
Purpose While general guidelines (such as CONSORT or Consensus on Exercise Reporting Template) exist to enhance the reporting of exercise interventions in the field of exercise science, there is inadequate detail facilitating the standardized reporting of resistance training adherence in the oncology setting. The purpose of this study was to apply a novel method to report resistance training dose, adherence, and tolerance in patients with cancer. Methods A total of 47 prostate cancer patients (70.1 ± 8.9 yr, body mass index, 28.6 ± 4.0) with bone metastatic disease completed an exercise program for 12 wk. We assessed traditional metrics of adherence (attendance and loss to follow-up), in addition to novel proposed metrics (exercise-relative dose intensity, dose modification, and exercise interruption). Total training volume in kilograms (repetitions × sets × training load (weight)) was calculated for each patient. Results Attendance assessed from traditional metrics was 79.5% ± 17.0% and four patients (9%) were lost to follow-up. The prescribed and actual cumulative total dose of resistance training was 139,886 ± 69,150 kg and 112,835 ± 83,499 kg, respectively, with a mean exercise-relative dose intensity of 77.4% ± 16.6% (range: 19.4% –99.4%). Resistance training was missed (1–2 consecutive sessions) or interrupted (missed ≥3 consecutive sessions) in 41 (87%) and 24 (51%) participants, respectively. Training dose was modified (reduction in sets, repetitions, or weight) in 40 (85%) of patients. Importantly, using attendance as a traditional metric of adherence, these sessions would have all counted as adherence to the protocol. Conclusions Traditional reporting metrics of resistance training in exercise oncology may overestimate exercise adherence. Our proposed metrics to capture resistance training dose, adherence, and tolerance may have important applications for future studies and clinical practice.This publication has 31 references indexed in Scilit:
- The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitorsObesity, 2016
- Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical TrialJournal of Clinical Oncology, 2015
- Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trialBMC Medicine, 2015
- Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapyActa Oncologica, 2015
- Top 10 Research Questions Related to Physical Activity and Cancer SurvivorshipResearch Quarterly for Exercise and Sport, 2015
- A Multicentre Year-long Randomised Controlled Trial of Exercise Training Targeting Physical Functioning in Men with Prostate Cancer Previously Treated with Androgen Suppression and Radiation from TROG 03.04 RADAREuropean Urology, 2014
- Effects of exercise dose and type on sleep quality in breast cancer patients receiving chemotherapy: a multicenter randomized trialBreast Cancer Research and Treatment, 2014
- Effects of Exercise Dose and Type During Breast Cancer Chemotherapy: Multicenter Randomized TrialJNCI Journal of the National Cancer Institute, 2013
- Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled TrialJournal of Clinical Oncology, 2010
- Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled TrialJournal of Clinical Oncology, 2007